Erika Hamilton MD

Oncology•Nashville, TN

Physician

Join to View Full Profile

250 25th Ave NSuite 100Nashville, TN 37203
Phone+1 615-320-5090
Fax+1 615-320-1225

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2013
University of North Carolina HospitalsResidency, Internal Medicine, 2007 - 2009
University of North Carolina at Chapel Hill School of MedicineClass of 2007

Certifications & Licensure

TN State Medical License 2013 - 2027
NC State Medical License 2007 - 2014
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Start of enrollment: 2014 Feb 28
Completed
Phase 1
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Start of enrollment: 2013 Dec 31
Completed
Phase 1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 1, Phase 2
AZD9496 First Time in Patients Ascending Dose Study Start of enrollment: 2014 Oct 22
Completed
Phase 1
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors. Start of enrollment: 2015 Sep 23
Completed
Phase 1
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Start of enrollment: 2016 Jun 29
Completed
Phase 1
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Start of enrollment: 2016 Oct 01
Terminated
Phase 1
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Start of enrollment: 2016 Dec 01
Completed
Phase 1
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Start of enrollment: 2020 Jul 23
COMPLETED
PHASE3
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Start of enrollment: 2020 Jun 29
COMPLETED
PHASE1
A Study of Fruquintinib in Combination with Tislelizumab in Advanced Solid Tumors Start of enrollment: 2021 Aug 09
TERMINATED
PHASE1, PHASE2
Roles: Principal Investigator, Contact
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Start of enrollment: 2016 Nov 01
COMPLETED
PHASE1
Roles: Contact
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Contact, Principal Investigator
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Start of enrollment: 2022 Dec 07
RECRUITING
PHASE1, PHASE2
Roles: Contact
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers Start of enrollment: 2023 Jan 11
RECRUITING
PHASE1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

5 citations
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park
Journal of Clinical Oncology. 2025-03-20
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive
Nature Medicine. 2025-03-01
1 citations
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Sarina Piha-Paul, Shane A Olwill, Erika Hamilton, Anthony Tolcher, Paula Pohlmann
Clinical Cancer Research. 2025-01-17

Lectures

The Metastatic Breast Cancer Project: Engaging Patients, Advancing Research
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC...
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
The Elusive Hunt for CDK Inhibitor Biomarkers
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Tox Check: Antibody Drug ConjugatesNovember 19th, 2024
More Younger Women and Asian Americans Are Getting Diagnosed with Breast CancerOctober 28th, 2024
Breast Cancer Awareness Month: Common Myths About the DiseaseOctober 13th, 2024
Join now to see all

Erika Hamilton MD

Dr. Hamilton is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.